Date: 2016-04-04
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Endocrine Society's Annual Meeting — ENDO 2016
Company: Xoma (USA - CA)
Product: XOMA 129
Action
mechanism: monoclonal antibody. XOMA 129 is a fully human, high affinity monoclonal antibody fragment that specifically targets the human insulin receptor (INSR). As a negative allosteric modulator, XOMA 129 binds with high affinity to a site distinct from insulin binding and dampens insulin signaling. This drug candidate has been designed to provide a rapid onset of action and a duration of action tailored to meet the pharmacotherapy needs in certain conditions.
Disease: severe acute hypoglycemia
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On April 4, 2016, Xoma announced the presentation of data from XOMA 129, the lead compound in its XMetD antibody fragment (Fab) program, at the Endocrine Society's Annual Meeting — ENDO 2016. A senior scientist at XOMA presented the Company's poster titled "XOMA 129, a Novel Insulin Receptor Negative Modulator, is Efficacious in Treating Insulin- and Glibenclamide-induced Hypoglycemia in Animals." The poster outlines XOMA 129's performance in separate pre-clinical models: cell culture and animal pharmacology studies. In vitro assays showed XOMA 129 decreases the activity of insulin on mammalian cells over-expressing human, rat and minipig insulin receptor (INSR) in a dose-dependent manner. Further studies confirmed XOMA 129 binds to the INSR and acts as a negative allosteric modulator. In animal studies, potential rescue of insulin or sulphonylurea-induced hypoglycemia was modeled in normal rats. Administration of insulin or glibenclamide (a sulfonylurea) produced abnormally low glucose levels. Intravenous administration of XOMA 129 at time points wherein the drug-induced glucose levels were falling below normal levels rapidly stabilized blood glucose levels thereby preventing hypoglycemia. In normal minipigs, intramuscular administration yielded significant elevation of blood glucose lasting for several hours thereby confirming the activity in mammals. Xoma intends to advance XOMA 129t into Phase 1 testing as soon as possible.
